Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet...
, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen...
View ArticleViiV Healthcare begins phase III programme with dolutegravir/rilpivirine...
(Source: GSK - GlaxoSmithKline plc) 06 May 2015 First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine London, United Kingdom, 6 May 2015: ViiV Healthcare today...
View ArticleViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine...
First programme to evaluate dual HIV maintenance therapy with dolutegravir and rilpivirine LONDON, May 6, 2015 /CNW/ - ViiV Healthcare today announced the start of a Phase III clinical trial programme...
View ArticleJanssen to Progress Collaboration with ViiV Healthcare to Develop the First...
(Source: Johnson & Johnson) 5bdf0770-87c8-4b68-992a-859cfe2ae0b0.pdf January 7, 2016 Janssen to Progress Collaboration with ViiV Healthcare to Develop the First Long Acting Two Drug Injectable...
View ArticleFirst Investigational All Injectable Long Acting HIV Combination Regimen...
(Source: Johnson & Johnson) 4276210d-1972-426f-bab1-761478e35fc7.pdf November 3, 2015 First Investigational All Injectable Long Acting HIV Combination Regimen Study Results at 32 Weeks Announced...
View ArticleLupin Bolsters US Brands Portfolio with Methergine® Oral Tablets
MUMBAI, India and BALTIMORE, April 28, 2016 /PRNewswire/ -- The only FDA-approved oral uterotonic for the management of PPH, comes to market with a significant investment in professional medical...
View ArticleBristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for...
(Source: Bristol-Myers Squibb Company) BMS-663068 is the first investigational antiretroviral designed to prevent HIV attachment to and entry into CD4+ T cells FDA Breakthrough Designation recognizes...
View ArticleOLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral...
OLYSIO(R) (simeprevir) Logo Facebook Twitter Pinterest OLYSIO(R) (simeprevir) bottle Facebook Twitter Pinterest Janssen Logo Facebook Twitter Pinterest × OLYSIO(R) (simeprevir) Logo OLYSIO(R)...
View ArticleJanssen Highlights its Hepatitis C Clinical Development Program in Advance of...
Janssen Logo. Facebook Twitter Pinterest × Janssen Logo. BOSTON, Nov. 7, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) highlights its hepatitis C (HCV) clinical development program in advance...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
(Source: Johnson & Johnson) July 23, 2015 Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir Filing Supported...
View ArticleJanssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral,...
TITUSVILLE, N.J., July 23, 2015 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the...
View ArticleJanssen Announces Collaboration with Gilead to Develop PREZISTA®-based...
-- Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union -- CORK, Ireland, Dec. 29, 2014 /CNW/ - Janssen R&D Ireland (Janssen)...
View ArticleJanssen Announces Collaboration with Gilead to Develop PREZISTA®-based...
Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) Facebook Twitter Pinterest × Janssen Logo. (PRNewsFoto/Janssen Pharmaceutical Companies) CORK, Ireland, December 29, 2014 /PRNewswire/ -- --...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Tablets Facebook Twitter Pinterest PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Bottle Facebook Twitter Pinterest PREZCOBIX(TM) Logo Facebook...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
(Source: Johnson & Johnson) Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, NJ, January 29, 2015...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
(Source: AbbVie Inc) - TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically...
View ArticleTECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
- TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically considered...
View Article